Key Points
- Vaxcyte COO Jim Wassil sold 2,250 shares on June 1 at an average price of $49.52, totaling about $111,420. The sale reduced his direct ownership by 1.40% and was made under a pre-arranged Rule 10b5-1 trading plan.
- The stock was trading lower, opening at $46.93 and down about 1.0% on the day. Vaxcyte’s shares have ranged from $29.08 to $65.00 over the past year.
- Vaxcyte recently reported a wider-than-expected loss of $2.30 per share for the quarter, missing analyst estimates of a $1.74 loss. Despite that, Wall Street’s consensus rating remains Moderate Buy with a target price of $86.00.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 2,250 shares of the business's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the transaction, the chief operating officer directly owned 158,494 shares of the company's stock, valued at approximately $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jim Wassil also recently made the following trade(s):
- On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.83, for a total value of $127,867.50.
- On Tuesday, March 10th, Jim Wassil sold 7,395 shares of Vaxcyte stock. The shares were sold at an average price of $58.88, for a total value of $435,417.60.
Vaxcyte Trading Down 1.0%
NASDAQ:PCVX opened at $46.93 on Thursday. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The stock has a market cap of $6.78 billion, a price-to-earnings ratio of -6.82 and a beta of 1.24. The stock has a 50-day moving average price of $55.49 and a two-hundred day moving average price of $52.76.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.56). During the same quarter in the previous year, the business earned ($1.04) earnings per share. Sell-side analysts forecast that Vaxcyte, Inc. will post -7.85 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of PCVX. Smartleaf Asset Management LLC boosted its position in Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company's stock valued at $27,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company's stock worth $30,000 after purchasing an additional 600 shares during the period. EverSource Wealth Advisors LLC raised its stake in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company's stock valued at $34,000 after buying an additional 184 shares during the period. Allworth Financial LP lifted its position in shares of Vaxcyte by 148.9% in the third quarter. Allworth Financial LP now owns 1,222 shares of the company's stock valued at $44,000 after buying an additional 731 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Vaxcyte during the 3rd quarter worth approximately $45,000. 96.78% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on the company. Wall Street Zen cut Vaxcyte from a "sell" rating to a "strong sell" rating in a research report on Tuesday, April 28th. BTIG Research upped their price objective on Vaxcyte from $85.00 to $89.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Vaxcyte currently has an average rating of "Moderate Buy" and a consensus target price of $86.00.
Get Our Latest Analysis on Vaxcyte
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
